Viridian Therapeutics, Inc. (VRDN)
18.66
+0.32
(+1.74%)
USD |
NASDAQ |
Oct 09, 16:00
18.69
+0.03
(+0.16%)
Pre-Market: 20:00
Viridian Therapeutics Cash from Investing (Quarterly) : -231.16M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -231.16M |
| March 31, 2026 | 77.26M |
| December 31, 2025 | -339.42M |
| September 30, 2025 | 126.08M |
| June 30, 2025 | 75.72M |
| March 31, 2025 | 100.06M |
| December 31, 2024 | -62.92M |
| September 30, 2024 | -84.67M |
| June 30, 2024 | 61.98M |
| March 31, 2024 | -143.04M |
| December 31, 2023 | -169.71M |
| September 30, 2023 | 48.04M |
| June 30, 2023 | 40.71M |
| March 31, 2023 | -13.30M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | 13.96M |
| March 31, 2022 | 8.863M |
| December 31, 2021 | -80.21M |
| September 30, 2021 | 6.251M |
| June 30, 2021 | -11.20M |
| March 31, 2021 | 10.87M |
| December 31, 2020 | -52.43M |
| September 30, 2020 | -0.053M |
| June 30, 2020 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2020 | 2.001M |
| December 31, 2019 | 7.00M |
| September 30, 2019 | 11.02M |
| June 30, 2019 | 13.02M |
| March 31, 2019 | -2.82M |
| December 31, 2018 | 9.091M |
| September 30, 2018 | -6.014M |
| June 30, 2018 | -32.89M |
| March 31, 2018 | -0.095M |
| December 31, 2017 | -0.034M |
| September 30, 2017 | -0.063M |
| June 30, 2017 | -0.105M |
| March 31, 2017 | 1.236M |
| December 31, 2016 | 1.00M |
| September 30, 2016 | -1.247M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | -0.003M |
| December 31, 2015 | 0.027M |
| September 30, 2015 | -0.004M |
| June 30, 2015 | -0.024M |
| March 31, 2015 | -0.044M |
| December 31, 2014 | -0.2614M |
| September 30, 2014 | -0.0083M |
| June 30, 2014 | |
| March 31, 2014 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | -45.80M |
| TG Therapeutics, Inc. | 1.03M |
| Travere Therapeutics, Inc. | -206.29M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -105.32M |
| Cash from Financing (Quarterly) | 325.12M |
| Free Cash Flow | -335.52M |
| Free Cash Flow Per Share (Quarterly) | -0.9884 |
| Free Cash Flow to Equity (Quarterly) | -298.34M |
| Free Cash Flow to Firm (Quarterly) | -98.32M |
| Free Cash Flow Yield | -18.62% |